Phase 1 Study Initiated: NBI-1140675 for Neurological and Neuropsychiatric Conditions
March 5th 2025Neurocrine Biosciences has initiated a phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of NBI-1140675 for certain neurological and neuropsychiatric conditions, such as tardive dyskinesia.